Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:
Sign Up
| Overall Assessment |
Analysis |
Score |
|
None
|
Chong Kun Dang Pharmaceutical Corp outlines its climate-related operational obligations, noting that “As a company that is subject to Korean GHG Target Management, CKD is obliged to assess and report its emissions annually and is required to take additional actions, such as internal reduction activities if required,” but the company does not disclose any processes for governing its lobbying or policy advocacy. We found no evidence of oversight structures, named individuals or committees responsible for lobbying alignment, or mechanisms to ensure that direct or indirect lobbying by the company or any trade associations aligns with its climate commitments, indicating no transparency around its public policy engagement governance.
View Sources
|
E
|
| Overall Assessment |
Analysis |
Score |
|
Limited
|
Chong Kun Dang Pharmaceutical Corp provides only a limited window into its climate-policy lobbying. It is transparent about which regulations it relates to, explicitly naming both the “Korean Emissions Trading Scheme (K-ETS)” and the “GHG and Energy Target Management System” and outlining how those systems allocate allowances, set control targets and apply fines, so the policies it follows are identifiable. Beyond citing its regulatory obligations, however, the company offers no insight into how it tries to shape these rules: it does not describe any meetings, submissions, letters, industry-association work, or the government bodies or officials it might approach. The only policy stance disclosed is that it offers “support for the Korean Emissions Trading Scheme (K-ETS) without exceptions,” a high-level statement that gives no indication of any amendments or new measures it seeks. Because the company lists the policies but omits both the mechanisms of engagement and the concrete outcomes it pursues, its overall disclosure remains limited.
|
D
|